Compare Tactile Systems Technology, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 613 Million (Micro Cap)
32.00
NA
0.00%
-0.37
8.72%
2.80
Revenue and Profits:
Net Sales:
75 Million
(Quarterly Results - Mar 2026)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.81%
0%
-6.81%
6 Months
4.63%
0%
4.63%
1 Year
169.81%
0%
169.81%
2 Years
80.12%
0%
80.12%
3 Years
39.61%
0%
39.61%
4 Years
99.92%
0%
99.92%
5 Years
-53.48%
0%
-53.48%
Tactile Systems Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.98%
EBIT Growth (5y)
58.70%
EBIT to Interest (avg)
3.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.28
Tax Ratio
27.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
5.13%
ROE (avg)
4.37%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
2.80
EV to EBIT
18.18
EV to EBITDA
14.82
EV to Capital Employed
3.84
EV to Sales
1.62
PEG Ratio
1.53
Dividend Yield
NA
ROCE (Latest)
21.12%
ROE (Latest)
8.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 65 Schemes (37.61%)
Foreign Institutions
Held by 64 Foreign Institutions (13.26%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
75.30
61.30
22.84%
Operating Profit (PBDIT) excl Other Income
0.10
-2.80
103.57%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.80
-3.00
40.00%
Operating Profit Margin (Excl OI)
-20.40%
-74.10%
5.37%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 22.84% vs 0.33% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 40.00% vs -36.36% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
329.50
293.00
12.46%
Operating Profit (PBDIT) excl Other Income
35.90
29.00
23.79%
Interest
1.00
2.10
-52.38%
Exceptional Items
0.00
0.00
Consolidate Net Profit
19.10
17.00
12.35%
Operating Profit Margin (Excl OI)
88.90%
75.70%
1.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 12.46% vs 6.78% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.35% vs -40.35% in Dec 2024
About Tactile Systems Technology, Inc. 
Tactile Systems Technology, Inc.
Pharmaceuticals & Biotechnology
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.
Company Coordinates 
Company Details
1331 Tyler St NE Ste 200 , MINNEAPOLIS MN : 55413-1638
Registrar Details






